Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration
- PMID: 28416553
- PMCID: PMC5487628
- DOI: 10.1128/AAC.00464-17
Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration
Abstract
Ceftazidime-avibactam administered at 1.25 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa bacteremia in a critically ill patient on continuous venovenous hemofiltration (CVVH). Prefiltration plasma drug concentrations of ceftazidime and avibactam were measured at 0, 1, 2, 4, 6, and 8 h along with postfiltration and ultrafiltrate concentrations at h 2 and h 6. Plasma pharmacokinetic parameters of ceftazidime and avibactam, respectively, were as follows: maximum plasma concentration (Cmax), 61.10 and 14.54 mg/liter; minimum plasma concentration (Cmin), 31.96 and 8.45 mg/liter; half-life (t1/2), 6.07 and 6.78 h; apparent volume of distribution at the steady state (Vss), 27.23 and 30.81 liters; total clearance at the steady state (CLss), 2.87 and 2.95 liters/h; area under the concentration-time curve from 0 to 8 h (AUC0-8), 347.87 and 85.69 mg · h/liter. Concentrations of ceftazidime in plasma exceeded the ceftazidime-avibactam MIC (6 mg/liter) throughout the 8-h dosing interval. Mean CVVH extraction ratios for ceftazidime and avibactam were 14.44% and 11.53%, respectively, and mean sieving coefficients were 0.96 and 0.93, respectively. The calculated mean clearance of ceftazidime by CVVH was 1.64 liters/h and for avibactam was 1.59 liters/h, representing 57.1% of the total clearance of ceftazidime and 54.3% of the total clearance of avibactam. Further data that include multiple patients and dialysis modes are needed to verify the optimal ceftazidime-avibactam dosing strategy during critical illness and CVVH.
Keywords: avibactam; ceftazidime; dialysis; hemofiltration; pharmacokinetics; renal replacement.
Copyright © 2017 American Society for Microbiology.
Figures

References
-
- . September 2015. Avycaz (ceftazidime/avibactam) prescribing information. Actavis, Inc; http://pi.actavis.com/data_stream.asp?product_group=1957&p=pi&language=E Accessed 14 September 2015.
-
- . 5 December 2014. Food and Drug Administration Anti-Infective Drugs Advisory Committee Meeting. Ceftazidime-avibactam for injection for treatment of complicated intra-abdominal infection (used in combination with metronidazole), complicated urinary tract infection including acute pyelonephritis, and limited use indication: aerobic Gram-negative infections with limited treatment options. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria... Accessed 25 August 2016.
-
- Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 28 December 2016. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother doi:10.1128/aac.02097-16. - DOI - PMC - PubMed
-
- Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. 2017. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 49:266–268. doi:10.1016/j.ijantimicag.2016.11.005. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical